News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Surana is a chartered accountant with an all-India rank.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
35 million mosquito nets supplied to countries in sub-Saharan Africa through partners
Subscribe To Our Newsletter & Stay Updated
